Long‐term Survival in Head and Neck Cancer: Impact of Site, Stage, Smoking, and Human Papillomavirus Status

Du, Eugenie; Mazul, Angela L.; Farquhar, Douglas R.; Brennan, Paul; Anantharaman, Devasena; Abedi‐Ardekani, Behnoush; Weissler, Mark C.; Hayes, D. Neil; Olshan, Andrew F.; Zevallos, José P.

doi:10.1002/lary.27807

Cited by 181 publications

(181 citation statements)

References 31 publications

Supporting

Mentioning

162

Contrasting

Unclassified

Order By: Relevance

“…In both OC and oropharyngeal cancer, we observed an increase in mortality risk for patients aged 460 years and those with stage III/IV SCC, which is similar to the findings reported by Ridder et al (15). Although a greater mortality risk was reported in men (15,21,23,24), this study did not find a survival difference between sexes.…”

Section: ' Discussionsupporting

confidence: 91%

See 1 more Smart Citation

Survival trends of patients with oral and oropharyngeal cancer treated at a cancer center in São Paulo, Brazil

Kowalski¹,

Oliveira²,

López³

et al. 2020

Clinics

View full text Add to dashboard Cite

OBJECTIVE:We aimed to estimate the overall survival (OS) and conditional survival (CS) in patients diagnosed with oral and oropharyngeal squamous cell carcinoma (SCC) and to determine their survival trends. METHODS:The study included all consecutive patients treated at the A.C. Camargo Cancer Center for oral or oropharyngeal SCC between 2001 and 2012. Data were obtained from the Hospital Cancer Registry. OS and CS were analyzed using the Kaplan-Meier method to evaluate the probability of survival with Cox predictor models. RESULTS: Data of 505 oral and 380 oropharyngeal SCC patients obtained in 2001-2006 and 2007-2012 were analyzed. Most of the oral SCC (59%) and oropharyngeal SCC (90%) patients had stages III-IV SCC. The 5-year OS for patients with oral SCC was 51.7%, with no significant difference between the first and second periods. The CS rates in 2007-2012 were 65% after the first year and 86% up to the fifth year. For oropharyngeal SCC, the 5-year OS rate was 45.0% in the first period. The survival rate increased to 49.1% from 2007 to 2012, with a reduction in the risk of death (HR=0.69;0.52-09.2). The CS estimates from 2007 to 2012 were 59% after the first year and 75% up to the fifth year. CONCLUSION: Survival across the two time periods remained stable for oral SCC but showed a significant increase for oropharyngeal SCC, possibly because of improvements in the patients' response to radiotherapy, such as intensity-modulated radiation therapy, and the use of more accurate diagnostic imaging approaches.

show abstract

Section: ' Discussionsupporting

confidence: 91%

“…For locally advanced oropharyngeal cancer, chemotherapy combined with radiation treatment has been reported to significantly improve OS (33,34). Du et al (23) observed that 84% of oropharyngeal cancer patients had stage III-IV cancers, which is the same as the finding of this study (90%). Monteiro (35).…”

Section: ' Discussionsupporting

confidence: 84%

Survival trends of patients with oral and oropharyngeal cancer treated at a cancer center in São Paulo, Brazil

Kowalski¹,

Oliveira²,

López³

et al. 2020

Clinics

View full text Add to dashboard Cite

show abstract

“…Sarcopenia and its effect on treatmentrelated complications and the clinical prognosis of HNC have recently attracted research attention. However, underestimation of the importance of sarcopenia continues to evolve when compared to the large number of studies that have been focused on different patient-and disease-related variables affecting the prognosis of patients with HNC (13)(14)(15)(16).…”

Section: Introductionmentioning

confidence: 99%

When the Loss Costs Too Much: A Systematic Review and Meta-Analysis of Sarcopenia in Head and Neck Cancer

et al. 2020

View full text Add to dashboard Cite

Whether or not skeletal muscle mass (SMM) depletion, known as sarcopenia, has significant negative effects on the prognosis of patients with head and neck cancer (HNC) is both new and controversial. In this meta-analysis, we aimed to determine the prognostic significance of sarcopenia in HNC. Methods: We searched PubMed, the Cochrane Library, Embase, and Web of Science, which contain trial registries and meeting proceedings, to identify related published or unpublished studies. We used the Newcastle-Ottawa Scale (NOS) to appraise the risk of bias of the included retrospective studies. Pooled hazard ratios (HR) and the I 2 statistic were estimated for the impact of sarcopenia on overall survival (OS) and relapse-free survival (RFS). Results: We analyzed data from 11 studies involving 2,483 patients (39.4% on average of whom had sarcopenia). Based on the univariate analysis data, the sarcopenia group had significantly poorer OS compared to the non-sarcopenia group [HR = 1.97, 95% confidence interval (CI): 1.71-2.26, I 2 = 0%]. In the cutoff value subgroup, group 1, defined as skeletal muscle index (SMI) of 38.5 cm 2 /m 2 for women and 52.4 cm 2 /m 2 for men (HR = 2.41, 95% CI: 1.72-3.38, I 2 = 0%), had much poorer OS. In the race subgroup, the results were consistent between the Asia (HR = 2.11, 95% CI: 1.59-2.81) and non-Asia group (HR = 1.92, 95% CI: 1.64-2.25). The sarcopenia group also had significantly poorer RFS (HR = 1.74, 95% CI: 1.43-2.12, I 2 = 0%). Conclusions: Presence of pre-treatment sarcopenia has a significant negative impact on OS and RFS in HNC compared with its absence. Further well-conducted studies with detailed stratification are needed to complement our findings.

show abstract

“…Approximately 95% of HNC cases are head and neck squamous carcinoma (HNSC), commonly arising from the mucosa of oral cavity, oropharynx, hypopharynx, and larynx [2,3]. The epidemiology surveys showed that smoking and alcohol consumption, and human papillomavirus (HPV) infection are most common causative factors for HNSC [4][5][6]. Although there have been certain advances in HNSC treatment, in stage III and IV HNSC, 5-year survival rate is less than 50% [7].…”

Section: Introductionmentioning

confidence: 99%

Profiles of immune cell infiltration in head and neck squamous carcinoma

Liang

Wang

2020

Bioscience Reports

View full text Add to dashboard Cite

Tumor immune infiltration cells (TIICs) are highly heterogeneous, not only in different cancer subtypes but also within different cancer regions. We conducted the Cell-type Identification using Estimating Relative Subsets Of RNA Transcripts (CIBERSORT) method. We assessed the relative proportions of 22 TIICs in HNSC using publicly available TCGA transcriptional datasets, analyzed the proportions of TIICs between HNSC tissues and normal tissues, along with accompanying clinicopathological data, and the impact of TIICs on clinical outcome. After the filter criteria, a total of 395 patients were included in the analysis. We found significant differences in naïve B cells, monocytes, resting mast cells, activated mast cells, CD8+ T cells, and M0 macrophages between HNSC tissues and adjacent non-cancer tissues. We also found that some TIIC subgroups were significantly associated with clinical parameters. Moreover, the patients with low Tregs fraction had worse OS and DFS than those with high Tregs fraction. However, low M0 macrophages fraction was associated with better OS and DFS in HNSC patients. Moreover, Tregs and M0 macrophages are likely to be important determinants of prognosis, which may serve as a potential immunotherapy target for HNSC. Then, we screened the immune-related differentially expressed genes (DEGs), performed the GO and KEGG enrichment analysis, constructed the protein–protein interaction network, and screened the prognosis-related hub genes in HNSC. However, further clinical investigation and basic experiments are needed to validate our results, and uncover the molecular mechanisms interlinking TIICs in HNSC and their roles in prognosis and therapy.

show abstract

Long‐term Survival in Head and Neck Cancer: Impact of Site, Stage, Smoking, and Human Papillomavirus Status

Cited by 181 publications

References 31 publications

Survival trends of patients with oral and oropharyngeal cancer treated at a cancer center in São Paulo, Brazil

Survival trends of patients with oral and oropharyngeal cancer treated at a cancer center in São Paulo, Brazil

When the Loss Costs Too Much: A Systematic Review and Meta-Analysis of Sarcopenia in Head and Neck Cancer

Profiles of immune cell infiltration in head and neck squamous carcinoma

Contact Info

Product

Resources

About